-transparent.png){kind=logo}
One-year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo. 1988
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
Division of Rheumatology, University of Utah Medical Center, Salt Lake City 84132.
Following a 21-week double-blind trial that compared the effects of treatment with auranofin (AUR), gold sodium thiomalate, and placebo in 193 patients, 147 patients entered a 1-year, open-label study of treatment with AUR (6 mg/day). Results of this open-label study suggest that AUR has a long-term use profile similar to that of other slow-acting antirheumatic drugs. AUR appears to be capable of sustaining an initial response to gold sodium thiomalate. The withdrawal rate remains relatively high: Nearly half of the study patients had discontinued AUR by the end of 1 year.
Related Publications
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
November 1983,
Arthritis and rheumatism,
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
February 1985,
The Journal of rheumatology,
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
June 1994,
Clinical rheumatology,
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
December 1990,
Clinical rheumatology,
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
February 1990,
Ryumachi. [Rheumatism],
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
March 1984,
Clinical rheumatology,
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
February 1988,
Klinische Wochenschrift,
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
August 1990,
British journal of rheumatology,
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
January 1982,
The Journal of rheumatology. Supplement,
H J Williams, and
S L Dahl, and
J R Ward, and
M Karg, and
R F Willkens, and
R F Meenan, and
M Altz-Smith, and
D O Clegg, and
W M Mikkelsen, and
D R Kay
December 1983,
The American journal of medicine,
